OSR Holdings, Inc. (NASDAQ:OSRH – Get Free Report)’s stock price rose 3.4% on Wednesday . The company traded as high as $0.4497 and last traded at $0.4207. Approximately 1,870,972 shares traded hands during trading, an increase of 2% from the average daily volume of 1,841,323 shares. The stock had previously closed at $0.4068.
Wall Street Analysts Forecast Growth
OSRH has been the subject of a number of recent research reports. Wall Street Zen raised shares of OSR from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Weiss Ratings restated a “sell (e+)” rating on shares of OSR in a research report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.
OSR Stock Down 6.7%
OSR (NASDAQ:OSRH – Get Free Report) last posted its earnings results on Wednesday, May 13th. The company reported ($0.09) EPS for the quarter. OSR had a negative return on equity of 7.24% and a negative net margin of 363.26%.The firm had revenue of $0.48 million during the quarter.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in OSR stock. Susquehanna International Group LLP bought a new position in OSR Holdings, Inc. (NASDAQ:OSRH – Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned about 0.37% of OSR at the end of the most recent quarter. Hedge funds and other institutional investors own 55.30% of the company’s stock.
About OSR
OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.
Further Reading
- Five stocks we like better than OSR
- AI Server Earnings: Wall Street Sees One Clear Standout
- Navitas: NVIDIA’s AI Power Broker?
- A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
- NVIDIA’s New Power Play: Why Fluence Is Surging
Receive News & Ratings for OSR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OSR and related companies with MarketBeat.com's FREE daily email newsletter.
